0001493152-17-005638.txt : 20170621 0001493152-17-005638.hdr.sgml : 20170621 20170519161511 ACCESSION NUMBER: 0001493152-17-005638 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170519 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEMISPHERX BIOPHARMA INC CENTRAL INDEX KEY: 0000946644 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 520845822 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1617 JFK BLVD, SUITE #500 STREET 2: ONE PENN CENTER CITY: PHILADELPHIA STATE: PA ZIP: 19103 BUSINESS PHONE: 215-988-0080 MAIL ADDRESS: STREET 1: 1617 JFK BLVD, SUITE #500 STREET 2: ONE PENN CENTER CITY: PHILADELPHIA STATE: PA ZIP: 19103 CORRESP 1 filename1.htm

 

HEMISPHERX BIOPHARMA, INC.

1617 JFK Boulevard

Philadelphia, Pennsylvania 19103

 

May 19, 2017

 

Suzanne Hayes, Esq.

Assistant Director

Division of Corporation Finance

Securities and Exchange Commission

100 F Street, NE

Washington, DC 20002

 

  Re: Hemispherx Biopharma, Inc.  
    Registration Statement on Form S-1  
    (SEC filing No. 333-217671)  
       
   

Acceleration Request

Requested Date: May 23, 2017

Requested Time: 4:00 P.M. Eastern Time

  

 

Dear Ms. Hayes:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Hemispherx Biopharma, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-217671) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Silverman Shin & Byrne PLLC, by calling Richard Feiner, Esq. at (646) 822-1170.

 

    Very truly yours,
     
    HEMISPHERX BIOPHARMA, INC.
     
  By: /s/Adam Pascale
  Adam Pascale,
  Chief Financial Officer

 

cc: Richard Feiner, Esq.